KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Equity: 2011-2025

Historic Return on Equity for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to -3.73%.

  • Nektar Therapeutics' Return on Equity fell 111.00% to -3.73% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.73%, marking a year-over-year decrease of 111.00%. This contributed to the annual value of -1.24% for FY2024, which is 13.00% down from last year.
  • Per Nektar Therapeutics' latest filing, its Return on Equity stood at -3.73% for Q3 2025, which was down 116.90% from 22.05% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Return on Equity ranged from a high of 22.05% in Q2 2025 and a low of -3.73% during Q3 2025.
  • Moreover, its 3-year median value for Return on Equity was -1.72% (2024), whereas its average is 0.05%.
  • Within the past 5 years, the most significant YoY rise in Nektar Therapeutics' Return on Equity was 2,376bps (2025), while the steepest drop was 209bps (2025).
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Return on Equity stood at -0.71% in 2021, then declined by 25bps to -0.96% in 2022, then plummeted by 94bps to -1.90% in 2023, then decreased by 27bps to -2.17% in 2024, then slumped by 111bps to -3.73% in 2025.
  • Its last three reported values are -3.73% in Q3 2025, 22.05% for Q2 2025, and -3.45% during Q1 2025.